BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18629630)

  • 1. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
    Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
    Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
    Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
    Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer.
    Hsieh SC; Kuo SN; Zheng YH; Tsai MH; Lin YS; Lin JH
    Anticancer Res; 2013 Nov; 33(11):4965-73. PubMed ID: 24222137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
    van Agthoven T; Sieuwerts AM; Meijer-van Gelder ME; Look MP; Smid M; Veldscholte J; Sleijfer S; Foekens JA; Dorssers LC
    J Clin Oncol; 2009 Feb; 27(4):542-9. PubMed ID: 19075277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seven In Absentia Homolog 2 (SIAH2) downregulation is associated with tamoxifen resistance in MCF-7 breast cancer cells.
    Interiano RB; Yang J; Harris AL; Davidoff AM
    J Surg Res; 2014 Jul; 190(1):203-9. PubMed ID: 24656476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
    Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
    Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease.
    Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW
    Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
    Chong K; Subramanian A; Sharma A; Mokbel K
    Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.
    van der Willik KD; Timmermans MM; van Deurzen CH; Look MP; Reijm EA; van Zundert WJ; Foekens R; Trapman-Jansen AM; den Bakker MA; Westenend PJ; Martens JW; Berns EM; Jansen MP
    Am J Cancer Res; 2016; 6(2):270-84. PubMed ID: 27186402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression.
    Chan P; Möller A; Liu MC; Sceneay JE; Wong CS; Waddell N; Huang KT; Dobrovic A; Millar EK; O'Toole SA; McNeil CM; Sutherland RL; Bowtell DD; Fox SB
    Breast Cancer Res; 2011 Feb; 13(1):R19. PubMed ID: 21306611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
    Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
    Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression and function of E3 ligase SIAH2 in acute T lymphoblastic leukemia.
    Chen H; Wang N; Yang G; Guo Y; Shen Y; Wang X; Zhang P; Xu Y
    Leuk Res; 2016 Mar; 42():28-36. PubMed ID: 26859780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
    Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
    J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.
    van Agthoven T; van Agthoven TL; Portengen H; Foekens JA; Dorssers LC
    Cancer Res; 1992 Sep; 52(18):5082-8. PubMed ID: 1516065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.